标题：慢性肾脏病合并房颤的机制及口服抗凝用药的研究进展

      作者：柳茜，罗欣月，朱春玲 综述 严瑞 审校    贵州医科大学附属医院肾内科，贵州 贵阳 550000

      卷次： 2021年32卷23期

      【摘要】 慢性肾脏病(CKD)患者房颤(AF)发病的病理生理机制复杂且多样化，包括炎症反应、肾素-血管紧张素-醛固酮系统激活、氧化应激、钙离子转运异常等，这一系列反应能增加卒中的风险，而预防性抗凝可以降低卒中风险。本文就目前CKD患者AF发病的机制及口服抗凝用药的研究进展进行综述。
      【关键词】 慢性肾脏病；房颤；肾素-血管紧张素-醛固酮系统；氧化应激；抗凝；华法林；直接口服抗凝药
      【中图分类号】 R692 【文献标识码】 A 【文章编号】 1003—6350（2021）23—3115—04

Mechanism of chronic kidney disease combined with atrial fibrillation and the research progress of oralanticoagulants.
LIU Xi, LUO Xin-yue, ZHU Chun-lin, YAN Rui. Department of Nephrology, the Affiliated Hospital ofGuizhou Medical University, Guiyang 550000, Guizhou, CHINA【Abstract】 The pathophysiological mechanisms of atrial fibrillation (AF) in patients with chronic kidney disease(CKD) are diverse and complicated, including inflammatory response, the activation of renin-angiotensin-aldosteronesystem (RAAS), oxidative stress, abnormal calcium ion transport. This series of reactions can significantly increase therisk of stroke, and preventive anticoagulation can reduce the risk of stroke. This paper reviews the mechanism of AF inCKD patients and the current research progress of oral anticoagulants.
      【Key words】 Chronic kidney disease (CKD); Atrial fibrillation (AF); Renin-angiotensin-aldosterone system(RAAS); Oxidative stress; Anticoagulant; Warfarin; Direct oral anticoagulants (DOAC)·综述·doi:10.3969/j.issn.1003-6350.2021.23.034基金项目：国家自然科学基金(编号：81960140)